CTOs on the Move

GW Pharmaceuticals

www.gwpharm.com

 
GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.gwpharm.com
  • 5750 Fleet Street Suite 200
    Carlsbad, CA USA 92008
  • Phone: 760.795.2200

Executives

Name Title Contact Details

Similar Companies

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical

Sanovia

Sanovia s corporate vision is to deliver state-of-the-art products and services which allow its customers to take advantage of advanced technology to improve communications, improve resource utilization through automated workflow processes, advance the quality and appropriateness of care through the integrated use of automated best-practice pharmaceutical clinical guidelines, and control costs.

Proacta

Proacta Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioProtection Systems Corporation

BioProtection Systems Corporation is a Ames, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.